Valneva Stock Enters Oversold Territory After a 37.5% Drop Over Three Months

Morning Trading Update

In mid-morning trading, Valneva is being traded at 2.609 euros, down 3.01% from the previous day's close of 2.69 euros. The stock is dangerously approaching its support level at 2.58 euros, a breach of which could lead to a new phase of decline. Over the week, the loss has already reached 7.55%. From a technical analysis perspective, the RSI stands at 29, indicating an oversold condition for the stock. Moreover, the price is significantly below its 50-day moving average of 4.08 euros and its 200-day average of 3.88 euros, confirming the underlying bearish trend. The stock's position in the lower part of the Bollinger Bands—at only 24% of the range between the lower boundary (1.67 euros) and the upper boundary (5.57 euros)—illustrates the magnitude of selling pressure accumulated in recent weeks.

Accelerated Deterioration in Valneva's Stock Price

The deterioration of Valneva's stock price has accelerated since the beginning of the year, with the stock showing a decline of nearly 37.5% over three months. Over a year, the performance remains negative at -12.57%. The Franco-Austrian vaccine specialist is experiencing a period of high volatility, measured at 23.21 over the past month, while its negative beta of -0.33 indicates a historically market-decoupled evolution. The next key dates on the financial calendar are the first quarter results scheduled for May 7, 2026, followed by the annual general meeting on June 1. These events will be closely monitored by the market to assess the operational trajectory of the group. In the European pharmaceutical sector, today's session shows mixed profiles: Sanofi is up by 0.36% while UCB is down by 0.97%, with no direct link to Valneva's own dynamics.